Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Bolt Biotherapeutics, Inc. (BOLT) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/07/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/07/2023 8-K Quarterly results
Docs: "Bolt Biotherapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update – First patients dosed in the BDC-1001 Phase 2 program – BDC-1001 Phase 1 data presented at ASCO 2023 demonstrated favorable safety profile and encouraging efficacy as a monotherapy and in combination with nivolumab in HER2-expressing tumors – BDC-3042 received IND clearance; clinical trial expected to start before year-end – Cash balance of $157.1 million anticipated to fund key milestones through 2025 REDWOOD CITY, Calif., August 7, 2023"
05/11/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/11/2023 8-K Quarterly results
Docs: "Bolt Biotherapeutics Reports First Quarter 2023 Financial Results and Provides Business Update – Comprehensive BDC-1001 clinical safety and efficacy data as a single agent and in combination with nivolumab, including RP2D, to be presented at ASCO 2023 – BDC-1001 Phase 2 program expected to initiate in 2023 in HER2+ colorectal, endometrial, gastroesophageal, and breast cancer – Cash balance of $171.0 million anticipated to fund key clinical milestones through 2025 REDWOOD CITY, Calif., May 11, 2023"
04/20/2023 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
03/29/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
03/29/2023 10-K Annual Report for the period ended December 31, 2022
03/29/2023 8-K Quarterly results
02/14/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/13/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/07/2023 5 Yonehiro Grant (Chief Business Officer) has filed a Form 5 on Bolt Biotherapeutics, Inc.
02/07/2023 5 Schatzman Randall C (CEO) has filed a Form 5 on Bolt Biotherapeutics, Inc.
02/07/2023 5 Perez Edith A. (Chief Medical Officer) has filed a Form 5 on Bolt Biotherapeutics, Inc.
02/07/2023 5 Quinn William P. (CFO) has filed a Form 5 on Bolt Biotherapeutics, Inc.
01/04/2023 SC 13D/A Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
12/28/2022 SC 13D/A Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
12/14/2022 8-K Quarterly results
11/10/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/10/2022 8-K Quarterly results
Docs: "Bolt Biotherapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update – BDC-1001 dose-escalation clinical trial on track to complete recruitment by year-end 2022 – BDC-3042 on track to enter the clinic in 2023; new preclinical data at SITC 2022 – Cash balance of $209.6 million anticipated to fund key milestones through 2025 REDWOOD CITY, Calif, Nov. 10, 2022"
09/30/2022 SC 13D/A Novo Holdings A/S reports a 9.8% stake in Bolt Biotherapeutics, Inc.
08/10/2022 10-Q Quarterly Report for the period ended June 30, 2022
08/10/2022 8-K Quarterly results
07/15/2022 SC 13D/A Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
06/10/2022 8-K Quarterly results
05/16/2022 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
05/12/2022 10-Q Quarterly Report for the period ended March 31, 2022
05/12/2022 8-K Quarterly results
04/28/2022 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/28/2022 DEF 14A Form DEF 14A - Other definitive proxy statements:
04/08/2022 EFFECT Form EFFECT - Notice of Effectiveness:
04/07/2022 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
03/30/2022 S-3 Form S-3 - Registration statement under Securities Act of 1933:
03/30/2022 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
03/30/2022 10-K Annual Report for the period ended December 31, 2021
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy